Lora Hamuro

ORCID: 0000-0003-2367-1926

Also affiliated with Bristol-Myers Squibb (Sweden)

Immunology and MicrobiologyMedicine

Pilot corpus only

This score is computed over theSindex pilot corpus and does not cover the full scientific literature. Scores are relative to papers we have ingested — papers, authors, and institutions outside the pilot are not represented. Methodology.

Top 100%percentile

0Author DataRank

Indexed papers

0in pilot corpus

datarank_citation_only_1hop_v6· scope data_onlyMethodology

Papers

Driven by 1 paper. Top paper: “Phase I study of BMS-986299, an NLRP3 agonist, as monotherapy and in combination with nivolumab and ipilimumab in patients with advanced solid tumors”.

Phase I study of BMS-986299, an NLRP3 agonist, as monotherapy and in combination with nivolumab and ipilimumab in patients with advanced solid tumors

Journal for ImmunoTherapy of Cancer(2025)10.1136/jitc-2024-010013

N/A

0.617DataRank · unranked

22 citations

Shaun O’Brien, Rahul A. Sheth, David S. Hong, Aung Naing, Xiao–Ping Zhang +7 more